{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:38:12Z","timestamp":1776181092338,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019670","name":"BIKEN Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fm0208101"],"award-info":[{"award-number":["JP20fm0208101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21fm0208101"],"award-info":[{"award-number":["JP21fm0208101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004051","name":"Kato Memorial Bioscience Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.virol.2022.09.005","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:59:41Z","timestamp":1664179181000},"page":"83-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle"],"prefix":"10.1016","volume":"576","author":[{"given":"Keita","family":"Mizuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Cubitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2022.09.005_bib1","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1067\/mob.2002.126297","article-title":"Lymphocytic choriomeningitis virus: emerging fetal teratogen","volume":"187","author":"Barton","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.virol.2022.09.005_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0166-0934(91)90018-U","article-title":"Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates","volume":"33","author":"Battegay","year":"1991","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.virol.2022.09.005_bib3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1994.1001","article-title":"Mechanism of lymphocytic choriomeningitis virus entry into cells","volume":"198","author":"Borrow","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.09.005_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000455","article-title":"Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa","volume":"5","author":"Briese","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.09.005_bib6","series-title":"Fields Virology","first-page":"1283","article-title":"Arenaviridae","author":"Buchmeier","year":"2013"},{"key":"10.1016\/j.virol.2022.09.005_bib7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.virol.2022.09.005_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","article-title":"Evaluation of Lassa antiviral compound ST-193 in a Guinea pig model","volume":"90","author":"Cashman","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.09.005_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.virol.2022.09.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104667","article-title":"A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity","volume":"173","author":"Cubitt","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.09.005_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","article-title":"Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study","volume":"25","author":"Dusheiko","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.virol.2022.09.005_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: a systematic review and meta-analysis","volume":"87","author":"Eberhardt","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1099\/0022-1317-43-1-247","article-title":"Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production","volume":"43","author":"Emeny","year":"1979","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib14","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.0900088106","article-title":"Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest","volume":"106","author":"Emonet","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2022.09.005_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/JVI.02102-10","article-title":"Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease","volume":"85","author":"Emonet","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa053240","article-title":"Transmission of lymphocytic choriomeningitis virus by organ transplantation","volume":"354","author":"Fischer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2022.09.005_bib17","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1073\/pnas.0600652103","article-title":"Recovery of an arenavirus entirely from RNA polymerase I\/II-driven cDNA","volume":"103","author":"Flatz","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virol.2022.09.005_bib18","first-page":"865","article-title":"Emerging infectious diseases and risk to the traveler","volume":"83","author":"Freedman","year":"1999","journal-title":"Med. Clin."},{"key":"10.1016\/j.virol.2022.09.005_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Jun\u00edn virus infection and reduces mortality in a Guinea pig model of Argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2013","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib20","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3201\/eid1612.100994","article-title":"Ribavirin for Lassa fever postexposure prophylaxis","volume":"16","author":"Hadi","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/514749","article-title":"Clinical case definitions for Argentine hemorrhagic fever","volume":"28","author":"Harrison","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib22","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1128\/JVI.78.24.13793-13803.2004","article-title":"Replicon system for Lassa virus","volume":"78","author":"Hass","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib23","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1086\/322620","article-title":"Viral hemorrhagic fever hazards for travelers in Africa","volume":"33","author":"Isaacson","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02256-17","article-title":"A highly conserved leucine in mammarenavirus matrix Z protein is required for Z interaction with the virus L polymerase and Z stability in cells harboring an active viral ribonucleoprotein","volume":"92","author":"Iwasaki","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006892","article-title":"Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+\/K+ transporting subunit Alpha 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses","volume":"14","author":"Iwasaki","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.09.005_bib26","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1128\/JVI.00103-15","article-title":"Efficient interaction between arenavirus nucleoprotein (NP) and RNA-dependent RNA polymerase (L) is mediated by the virus nucleocapsid (NP-RNA) template","volume":"89","author":"Iwasaki","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib27","doi-asserted-by":"crossref","first-page":"12166","DOI":"10.1128\/JVI.02075-15","article-title":"General molecular strategy for development of arenavirus live-attenuated vaccines","volume":"89","author":"Iwasaki","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib28","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.02110-13","article-title":"Sodium hydrogen exchangers contribute to arenavirus cell entry","volume":"88","author":"Iwasaki","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","article-title":"Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin","volume":"141","author":"Jahrling","year":"1980","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00524-15","article-title":"Single nucleoprotein residue modulates arenavirus replication complex formation","volume":"6","author":"Knopp","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.virol.2022.09.005_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3201\/eid2502.180836","article-title":"Lassa fever in travelers from west Africa, 1969-2016","volume":"25","author":"Kofman","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008900","article-title":"HER2-mediated enhancement of Ebola virus entry","volume":"16","author":"Kuroda","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.09.005_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2010.11.006","article-title":"Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa)","volume":"89","author":"Langhammer","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.09.005_bib34","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/JVI.74.8.3470-3477.2000","article-title":"NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs","volume":"74","author":"Lee","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/mc.22342","article-title":"Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells","volume":"55","author":"Lee","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.virol.2022.09.005_bib36","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.virol.2022.09.005_bib37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/0042-6822(92)90514-P","article-title":"Generation of reassortants between African arenaviruses","volume":"188","author":"Lukashevich","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.09.005_bib38","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1099\/vir.0.82808-0","article-title":"Characterization of Junin arenavirus cell entry","volume":"88","author":"Martinez","year":"2007","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib39","series-title":"Arenaviruses I: the Epidemiology, Molecular and Cell Biology of Arenaviruses","first-page":"75","article-title":"Lassa fever","author":"McCormick","year":"2002"},{"key":"10.1016\/j.virol.2022.09.005_bib40","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib41","doi-asserted-by":"crossref","first-page":"10924","DOI":"10.1128\/JVI.01587-15","article-title":"Identification and mechanism of action of a novel small-molecule inhibitor of arenavirus multiplication","volume":"89","author":"Ngo","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"Olschlager","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.09.005_bib44","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1128\/JVI.00257-16","article-title":"Lassa virus cell entry via dystroglycan involves an unusual pathway of macropinocytosis","volume":"90","author":"Oppliger","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa073785","article-title":"A new arenavirus in a cluster of fatal transplant-associated diseases","volume":"358","author":"Palacios","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2022.09.005_bib46","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3201\/eid1510.090211","article-title":"Nosocomial outbreak of novel arenavirus infection, southern Africa","volume":"15","author":"Paweska","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib47","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1128\/JVI.77.2.1184-1194.2003","article-title":"Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus","volume":"77","author":"Perez","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib48","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1056\/NEJMp068021","article-title":"Lymphocytic choriomeningitis virus--an old enemy up to new tricks","volume":"354","author":"Peters","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2022.09.005_bib49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib50","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.virol.2022.09.005_bib51","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.virol.2022.09.005_bib52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1099\/vir.0.061242-0","article-title":"Raf\/MEK\/ERK pathway activation is required for Junin virus replication","volume":"95","author":"Rodriguez","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib53","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1128\/JVI.00560-08","article-title":"Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses","volume":"82","author":"Rojek","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib54","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of favipiravir to treat lassa virus infection in macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2022.09.005_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0042-6822(02)00046-6","article-title":"Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV)","volume":"308","author":"Ruiz-Jarabo","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.09.005_bib56","doi-asserted-by":"crossref","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2022.09.005_bib57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.virol.2006.01.012","article-title":"Rescue of the prototypic Arenavirus LCMV entirely from plasmid","volume":"350","author":"Sanchez","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.virol.2022.09.005_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002657","article-title":"Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis","volume":"8","author":"Schelhaas","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2022.09.005_bib59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.antiviral.2011.10.007","article-title":"Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative","volume":"93","author":"Sepulveda","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2022.09.005_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/biom9110668","article-title":"FDA- and EMA-approved tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer: safety, tolerability, plasma concentration monitoring, and management","volume":"9","author":"Solassol","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.virol.2022.09.005_bib61","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/JVI.01520-07","article-title":"Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses","volume":"82","author":"Sun","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib62","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/JVI.02319-12","article-title":"Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-Kinase\/Akt\/mTOR pathway and inhibition of autophagy","volume":"87","author":"Surviladze","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib63","first-page":"199","article-title":"Design and construction of 2A peptide-linked multicistronic vectors","author":"Szymczak-Workman","year":"2012","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.virol.2022.09.005_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI25167","article-title":"Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals","volume":"116","author":"Tyner","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2022.09.005_bib65","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1128\/JVI.06604-11","article-title":"The PI3K\/Akt pathway contributes to arenavirus budding","volume":"86","author":"Urata","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2022.09.005_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/v13060976","article-title":"Activation of the STAT3 signaling pathway by the RNA-dependent RNA polymerase protein of arenavirus","volume":"13","author":"Wang","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2022.09.005_bib67","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nm1236","article-title":"Integrin alphavbeta3 is a coreceptor for human cytomegalovirus","volume":"11","author":"Wang","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2022.09.005_bib68","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nature01818","article-title":"Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus","volume":"424","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.virol.2022.09.005_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"10.1016\/j.virol.2022.09.005_bib70","first-page":"79","article-title":"Argentine hemorrhagic fever","volume":"134","author":"Weissenbacher","year":"1987","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.virol.2022.09.005_bib71","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm.2145","article-title":"Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6","volume":"16","author":"Weller","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2022.09.005_bib72","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.chom.2013.04.011","article-title":"Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry","volume":"13","author":"Wojcechowskyj","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.virol.2022.09.005_bib73","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682222001520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:57:52Z","timestamp":1758589072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682222001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":73,"alternative-id":["S0042682222001520"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2022.09.005","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Pan-ErbB tyrosine kinase inhibitor afatinib inhibits multiple steps of the mammarenavirus life cycle","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2022.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}